Section 08 · Editorial

An independent ledger of the BPC-157 TB-500 record

Who publishes this, what 'get' means here, and why the site reads as a restrained evidence ledger rather than a billboard.

About this editorial project

Wolverine Get is an independent editorial project that publishes summaries of the peer-reviewed research literature on the BPC-157 TB-500 blend and its two component peptides. We are not a clinic. We do not employ clinicians and we do not provide medical advice. We do not manufacture, sell, or distribute any product. Our work is editorial commentary on publicly available science.

The 'get' in the name is editorial framing, not a checkout. On this site it points at the access and regulatory question — where these substances can and cannot legitimately be obtained under the U.S. compounding framework — not at any offer to supply them. There is no cart here, no vendor, and no pharmacy behind the page. The Wolverine legal status page reads that access record off FDA sources and stops there.

We built this site as a ledger because the BPC-157 TB-500 record demands one. The blend is not a single approved drug with a clean data package; it is two distinct synthetic peptides — BPC-157 and the Ac-LKKTETQ fragment of Thymosin Beta-4 — whose 'synergy' is a theoretical extrapolation with no controlled combination trial behind it. A loud presentation would oversell that base. So we keep what the single-compound literature genuinely establishes in one tier, the many gaps and caveats one tier down and in plain sight, and the machine identifiers as quiet fine print.

Our method is narrow on purpose. We read primary sources — peer-reviewed studies indexed in PubMed, and the FDA's own published pages — and we attribute each claim where it was measured: which compound, which species, which dose, which route. We do not pool the two peptides' separate evidence into one combined claim, because no study has done that. We flag the doubled identity caveat around TB-500 (most efficacy data are for full-length Thymosin Beta-4, not the Ac-LKKTETQ fragment) wherever it applies, and we mark the regulatory facts as present-tense status, never as a prediction of future FDA action.

Every quantitative claim on the site maps to a numbered citation, and the full reference list is public. Where the honest answer is that no controlled human or combination data exist, we say so rather than fill the gap with forum protocol. If a claim is not in the cited record, it is not on this site. Corrections are welcome through the contact page; we update the ledger when a citation is wrong or a study has been superseded.